Utility of autologous fibrin glue in the donor site of free abdominal flap for breast reconstruction: A randomized controlled study

xlomafota13 shared this article with you from Inoreader Utility of autologous fibrin glue in the donor site of free abdominal flap for breast reconstruction: A randomized controlled study Via Journal of plastic, reconstructive & aesthetic surgery : JPRAS J Plast Reconstr Aesthet Surg. 2021 Apr 18:S1748-6815(21)00180-7. doi: 10.1016/j.bjps.2021.03.073. Online ahead of print. ABSTRACT BACKGROUND: Seroma formation at the donor site is a common complication of breast reconstruction using free abdominal flap. In this study, we assessed the benefits of use of autologous fibrin glue (AFG) at the donor site. METHODS: This randomized controlled study compared AFG group (n = 61) with commercial fibrin glue (CFG) group (n = 79). Owing to the high volume of AFG (10 mL), AFG group received fibrin glue at both the anastomosis and the donor sites, whereas CFG group received fibrin glue only at the anastomosis site. Operative protocols and the criteria for postoperative drain removal were identical in both groups. Patient characteristics and abdominal discharge were compared between the two groups. RESULTS: Since anemia was a contraindication for use of AFG, preoperative Hb in CFG group wa s significantly lower than that in AFG group; other factors were comparable in the two groups. The mean total abdominal drain volumes on first postoperative day (POD1) and POD2 was (AFG vs. CFG) 130.9 vs. 169.4 mL (P < 0.001) and 131.0 vs. 162.8 mL (P = 0.03), respectively. On POD3, there was no significant difference in this respect (116.2 vs. 128.4 mL, P = 0.19). The mean time for removal of all abdominal drains was significantly lower in AFG group (7.4 vs. 8.4 days; P = 0.01). CONCLUSIONS: AFG reduced the discharge at the donor site of free abdominal flap, especially in the early postoperative period. AFG helped to reduce the abdominal drainage period. PMID:33992561 | DOI:10.1016/j.bjps.2021.03.073 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.